This construct has then been used in 2003 in the same laboratory to create a pancreatic cancer predisposition model, in which the CRE recombinase expression is under the control of pancreas-specific gene promoters: Pdx1 or Ptf1a (p48), allowing a tissue-specific expression of KrasG12D (model named “KC”, for [LSL:KrasG12D;Pdx1 or Ptf1a-CRE])25. This evidence concerns the gene PTF1A and pancreatic neoplasm.